Literature DB >> 21545376

Clinical severity of haemophilia A: does the classification of the 1950s still stand?

I E M Den Uijl1, E P Mauser Bunschoten, G Roosendaal, R E G Schutgens, D H Biesma, D E Grobbee, K Fischer.   

Abstract

The classification of haemophilia originates from 1950s and has been adopted unchallengedly by the ISTH in 2001. The aim of this study was: does the current classification compare onset of bleeding and age at first treatment, as well as annual joint bleeding frequency according to baseline FVIII activity? Data on age and reason of diagnosis, onset of treatment, onset of bleeding and bleeding frequency from 411 patients with haemophilia A born after 1970 were collected. Data were analysed according to base-line FVIII activity levels. Age at diagnosis, onset of bleeding and start of treatment according to FVIII activity were compared with the current classification. Overall, the distinction between severe and non-severe haemophilia was clear. The distinction between mild and moderate haemophilia was more difficult, mostly due to the wide variability in the group of patients with moderate haemophilia. Patients with severe haemophilia experienced their milestones like diagnosis, first treatment and joint bleed earliest, mostly as infants aged 0-3 years, whereas patients with moderate haemophilia reached these milestones around toddler age, 2-7 years, and patients with mild haemophilia reached them when they were in elementary school, around the ages of 5-14 years. This study confirms the clinical distinction between severe and non-severe haemophilia A. However, the group of moderate haemophilia patients showed a wide variability, warranting close follow-up and individualized treatment.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21545376     DOI: 10.1111/j.1365-2516.2011.02539.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  57 in total

1.  [Prophylactic treatment with low- and intermediate-dose factor VIII in children with severe hemophilia A: comprehensive evaluation of joint outcomes and correlation analysis].

Authors:  Jin-Mu Zhuang; Xue-Yan Sun; Xuan Zhou; Zhu-Qin Liu; Jing Sun
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-04-20

Review 2.  Practical aspects of extended half-life products for the treatment of haemophilia.

Authors:  Thierry Lambert; Gary Benson; Gerry Dolan; Cedric Hermans; Victor Jiménez-Yuste; Rolf Ljung; Massimo Morfini; Silva Zupančić-Šalek; Elena Santagostino
Journal:  Ther Adv Hematol       Date:  2018-09-06

Review 3.  Advances and innovations in haemophilia treatment.

Authors:  Rob Peters; Tim Harris
Journal:  Nat Rev Drug Discov       Date:  2018-06-08       Impact factor: 84.694

4.  Target of prophylaxis in severe haemophilia: more than factor levels.

Authors:  Antonio Coppola; Massimo Franchini
Journal:  Blood Transfus       Date:  2012-12-21       Impact factor: 3.443

5.  Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.

Authors:  Elena Santagostino; Uri Martinowitz; Toshko Lissitchkov; Brigitte Pan-Petesch; Hideji Hanabusa; Johannes Oldenburg; Lisa Boggio; Claude Negrier; Ingrid Pabinger; Mario von Depka Prondzinski; Carmen Altisent; Giancarlo Castaman; Koji Yamamoto; Maria-Teresa Álvarez-Roman; Christine Voigt; Nicole Blackman; Iris Jacobs
Journal:  Blood       Date:  2016-01-11       Impact factor: 22.113

Review 6.  Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future.

Authors:  Victor Jiménez-Yuste; Günter Auerswald; Gary Benson; Thierry Lambert; Massimo Morfini; Eduardo Remor; Silva Zupančić Salek
Journal:  Blood Transfus       Date:  2014-07       Impact factor: 3.443

7.  Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.

Authors:  Annette Von Drygalski; Adam Giermasz; Giancarlo Castaman; Nigel S Key; Susan Lattimore; Frank W G Leebeek; Wolfgang Miesbach; Michael Recht; Alison Long; Robert Gut; Eileen K Sawyer; Steven W Pipe
Journal:  Blood Adv       Date:  2019-11-12

8.  Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.

Authors:  Lindsey A George; Spencer K Sullivan; Adam Giermasz; John E J Rasko; Benjamin J Samelson-Jones; Jonathan Ducore; Adam Cuker; Lisa M Sullivan; Suvankar Majumdar; Jerome Teitel; Catherine E McGuinn; Margaret V Ragni; Alvin Y Luk; Daniel Hui; J Fraser Wright; Yifeng Chen; Yun Liu; Katie Wachtel; Angela Winters; Stefan Tiefenbacher; Valder R Arruda; Johannes C M van der Loo; Olga Zelenaia; Daniel Takefman; Marcus E Carr; Linda B Couto; Xavier M Anguela; Katherine A High
Journal:  N Engl J Med       Date:  2017-12-07       Impact factor: 91.245

9.  Clinical and functional evaluation of the joint status of hemophiliac adults at a Brazilian blood center.

Authors:  Adriana Aparecida Ferreira; Maria Teresa Bustamante-Teixeira; Isabel Cristina Gonçalves Leite; Camila Soares Lima Corrêa; Daniela de Oliveira Werneck Rodrigues; Danielle Teles da Cruz
Journal:  Rev Bras Hematol Hemoter       Date:  2013

10.  Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy.

Authors:  Steffen Rosen; Stefan Tiefenbacher; Mary Robinson; Mei Huang; Jaydeep Srimani; Donnie Mackenzie; Terri Christianson; K John Pasi; Savita Rangarajan; Emily Symington; Adam Giermasz; Glenn F Pierce; Benjamin Kim; Stephen J Zoog; Christian Vettermann
Journal:  Blood       Date:  2020-11-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.